"It is gratifying to have our technologies validated with this contract award,” commented David Schwartz, Ph.D., CSO and co-founder of SoluLinK. “DARPA's confidence in our capabilities to develop these new devices based on SoluLinK’s precise and quantifiable conjugation and biomolecular detection capabilities are warranted. We look forward to reaching the contract objectives and the resulting device will be extremely valuable for rapidly triaging whole body radiation exposure.”
About SoluLinK
SoluLinK is a leader in the development of conjugation reagents, kits, and OEM products and services for the life sciences, diagnostic, and pharmaceutical communities with customers in over 30 countries worldwide. The company’s proprietary bioconjugation linking chemistry is used to link proteins, oligonucleotides, peptides, and antibodies to each other or to a wide range of surfaces. Rapidly growing applications for SoluLinK’s products include the conjugation of biomolecules for research assays, diagnostics, and pharmaceutical products. SoluLinK’s has also leveraged its competitive advantages into a series of easy to use kits, the ChromaLink
Biotin
Labeling Kit for protein biotinylation is one example. SoluLinK markets these products both directly and through distributors and licensing partners world-wide. SoluLinK is a privately held company located in San Diego, California. For more information, please visit www.solulink.com.
Contact
SoluLinK, Incorporated
Steve DeGraw
9853 Pacific Heights Blvd. Suite H,
San Diego, California 92121
T 858.625.0670
F 858.625.0770
solulink@solulink.com
